News | FDA | April 22, 2024

RCE Technologies, Inc. Announces First-In-Human Transdermal Continuous Cardiac Biomarker Monitoring

Latest research results involving groundbreaking wearable device unveiled at American College of Cardiology Conference in Atlanta (ACC.24)

RCE Technologies, Inc. (RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection.

RCE Technologies, Inc. (RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection.


April 22, 2024 — At the annual American College of Cardiology conference (ACC.24) in Atlanta last week, RCE Technologies, Inc., (RCE), an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection, highlighted results of a pilot study enrolling cardiac catheterization patients in the first-ever human trial of transdermal continuous cardiac biomarker monitoring, utilizing RCE’s Infrasensor™ wearable device.

Featured in an ACC.24 “Spotlight on Special Topics” presentation showcasing pioneering advancements in cardiac monitoring technology, the study marks a significant milestone in medical innovation. It was spearheaded by Ronald P. Karlsberg, MD, a Fellow of The American College of Cardiology and clinical professor of Medicine at both Cedars-Sinai Institute and UCLA, and led by Suhail Y. Dohad, MD, as principal investigator. Working with 20 consecutive patients encompassing both scheduled diagnostic catheterization procedures and emergency cases of heart attacks, clinical staff applied the Infrasensor wearable device to patients’ wrists before the procedure, enabling real-time continuous monitoring throughout coronary catheterization, extended monitoring in the post-anesthesia care unit (PACU), and removal just before hospital discharge.

“This is an innovative platform for measuring biomarkers,” stated Dr. Karlsberg. “The insights underscore the significant promise of this novel technology, which inaugurates a new era for monitoring in a wide variety of scenarios real-time and affords the opportunity to develop and refine diagnostic pathways that will have a substantial impact on patient care.”

The study builds on earlier findings presented at the ACC 2023 late-breaking clinical trials, where it was posited that exploring real-time biomarker trends from the wrist wearable could further the understanding of the transdermal signal and the association with clinically relevant use cases at the point of care.

RCE Technologies’ Founder/CEO Atandra Burman commented, “We are honored to have the collective dedication of esteemed clinicians and key opinion leaders in pushing the boundaries of medical exploration. This study highlights the value of digital biomarkers that may enable instantaneous feedback for care providers in assessing the patient. The insights lead us towards refining our understanding of the transdermal signals and our approach towards developing improved heart attack diagnostics.”

For more information: https://rce.ai/

 

Find more ACC24 conference coverage here


Related Content

News | ACC

July 31, 2024 — The American College of Cardiology (ACC) has announced its release of the ACC Remote Patient Management ...

Home July 31, 2024
Home
News | ACC

July 10, 2024 — Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal ...

Home July 10, 2024
Home
News | ACC

May 9, 2024 — The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new ...

Home May 09, 2024
Home
News | ACC

April 11, 2024 — One-year success rates from angioplasty procedures to open clogged arteries in the legs were ...

Home April 11, 2024
Home
News | ACC

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST ...

Home April 06, 2024
Home
Feature | ACC | Christine Book

April 3, 2024 — In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization ...

Home April 03, 2024
Home
News | ACC

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

Home March 26, 2024
Home
Feature | ACC | By Melinda Taschetta-Millane

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

Home March 25, 2024
Home
News | ACC

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal ...

Home March 21, 2024
Home
News | ACC

March 7, 2024 — The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd ...

Home March 07, 2024
Home
Subscribe Now